Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer

Author:

,Kelly M E1,Glynn R2,Aalbers A G J3,Abraham-Nordling M4,Alberda W5,Antoniou A6,Austin K K7,Beets G L3,Beynon J8,Bosman S J9,Brunner M10,Buchler M W11,Burger J W A5,Campain N12,Christensen H K13,Codd M2,Coscia M14,Colquhoun A J15,Daniels I R12,Davies R J15,de Wilt J H W16,Deutsch C15,Dietz D17,Eglinton T18,Fearnhead N15,Frizelle F A18,Garcia-Sabrido J L19,George M L20,Gentilini L14,Harris D A8,Harji D21,Heriot A G22,Hohenberger Brunner W10,Jenkins J T6,Kanemitsu Y23,Chan K K L24,Kim H25,Koh C E7,Kok N F3,Kontovounisios C26,Kulu Y27,Law W L24,Lê G N28,Lee P7,Lydrup M L29,Lynch A C22,Martling A4,Meijerink J30,Merkel S10,McDermott F D12,McGrath J S12,Nielsen Christensen M B13,Nieuwenhuijzen G A P9,Nordling M A4,Northover J M A6,O'Connell P R1,Patsouras D20,Poggioli G14,Radwan R W8,Rasheed S26,Rasmussen P C13,Rothbarth J31,Rutten H J T9,Sagar P M21,Schizas A M P20,Shida D23,Smart N J12,Solomon M J7,Stocchi L25,Tekkis P P26,Tsukamoto S23,Turner W H15,Tuynman J30,Ulrich A27,van Leeuwenhoek A3,van Ramshorst G H30,Vasquez-Jimenez W19,Verhoef C5,Versteegen M16,Wakeman C18,Warrier S22,Yip J24,Winter D C1

Affiliation:

1. Centre for Colorectal Disease, St Vincent's University Hospital, Dublin, Ireland

2. Centre for Support and Training in Analysis and Research, University College Dublin, Dublin, Ireland

3. Netherlands Cancer Institute, Amsterdam, The Netherlands

4. Karolinska University Hospital, Stockholm, Sweden

5. Erasmus Medical Centre, Rotterdam, The Netherlands

6. St Mark's Hospital, Harrow, UK

7. Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

8. Singleton Hospital, Swansea, UK

9. Catharina Hospital, Eindhoven, The Netherlands

10. Erlangen Hospital, Erlangen, Germany

11. Heidelberg University Hospital, Heidelberg, Germany

12. Royal Devon and Exeter Hospital, Exeter, UK

13. Aarhus University Hospital, Aarhus, Denmark

14. Sant'Orsola-Malpighi Hospital, Bologna, Italy

15. Addenbrooke's Hospital, Cambridge, UK

16. Radboud University Medical Centre, Nijmegen, Netherlands

17. University Hospitals of Cleveland, Cleveland, Ohio, USA

18. Christchurch Hospital, Christchurch, New Zealand

19. Gregorio Maranon General University Hospital, Madrid, Spain

20. Guy's and St Thomas' Hospital, London, UK

21. Leeds General Infirmary, Leeds, UK

22. Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

23. National Cancer Centre, Tokyo, Japan

24. Queen Mary Hospital, Hong Kong, China

25. Cleveland Clinic, Cleveland, Ohio, USA

26. Royal Marsden Hospital, London, UK

27. University of Heidelberg, Heidelberg, UK

28. Dublin City University, Dublin, Ireland

29. Skåne University Hospital, Lund, Sweden

30. VU University Medical Centre, Amsterdam, The Netherlands

31. Erasmus MC Cancer Institute, The Netherlands

Abstract

Abstract Background Pelvic exenteration for locally recurrent rectal cancer (LRRC) is associated with variable outcomes, with the majority of data from single-centre series. This study analysed data from an international collaboration to determine robust parameters that could inform clinical decision-making. Methods Anonymized data on patients who had pelvic exenteration for LRRC between 2004 and 2014 were accrued from 27 specialist centres. The primary endpoint was survival. The impact of resection margin, bone resection, node status and use of neoadjuvant therapy (before exenteration) was assessed. Results Of 1184 patients, 614 (51·9 per cent) had neoadjuvant therapy. A clear resection margin (R0 resection) was achieved in 55·4 per cent of operations. Twenty-one patients (1·8 per cent) died within 30 days and 380 (32·1 per cent) experienced a major complication. Median overall survival was 36 months following R0 resection, 27 months after R1 resection and 16 months following R2 resection (P < 0·001). Patients who received neoadjuvant therapy had more postoperative complications (unadjusted odds ratio (OR) 1·53), readmissions (unadjusted OR 2·33) and radiological reinterventions (unadjusted OR 2·12). Three-year survival rates were 48·1 per cent, 33·9 per cent and 15 per cent respectively. Bone resection (when required) was associated with a longer median survival (36 versus 29 months; P < 0·001). Node-positive patients had a shorter median overall survival than those with node-negative disease (22 versus 29 months respectively). Multivariable analysis identified margin status and bone resection as significant determinants of long-term survival. Conclusion Negative margins and bone resection (where needed) were identified as the most important factors influencing overall survival. Neoadjuvant therapy before pelvic exenteration did not affect survival, but was associated with higher rates of readmission, complications and radiological reintervention.

Publisher

Oxford University Press (OUP)

Subject

Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3